Literature DB >> 22105642

International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18.

Wei-Chu Chie1, Jane M Blazeby, Chin-Fu Hsiao, Herng-Chia Chiu, Ronnie T Poon, Naoko Mikoshiba, Gillian Al-Kadhimi, Nigel Heaton, Jozer Calara, Peter Collins, Katharine Caddick, Anna Costantini, Valerie Vilgrain, Ludovic Trinquart, Chieh Chiang.   

Abstract

UNLABELLED: This international field validation study examined the psychometric properties and clinical validity of the European Organization for Research and Treatment of Cancer (EORTC) questionnaire module for hepatocellular carcinoma (HCC), the EORTC quality-of-life questionnaire (QLQ)-HCC18. The EORTC QLQ-HCC18 was administered with the core questionnaire, the EORTC QLQ-C30, to 272 patients from seven centers in 6 countries. Patient acceptability of the module was examined with a debriefing questionnaire, and psychometric and clinical properties were assessed. Multitrait scaling analyses confirmed the hypothesized scale structure without any scaling error, and the fatigue scale demonstrated satisfactory internal consistency. The test-retest reliability scores were high for all scales, except abdominal swelling and sexual interest. The correlations between all scales of the QLQ-HCC18 and the QLQ-C30 were low or moderate, and many scales could distinguish patients with different clinical conditions. The module demonstrated responsiveness to clinical change in pain before and after surgery and some borderline change in patients undergoing systemic treatment.
CONCLUSION: The EORTC QLQ-HCC18 can be used as a supplementary module for the EORTC QLQ-C30 in clinical trials for patients with HCC.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22105642     DOI: 10.1002/hep.24798

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

Review 1.  Measuring symptoms in gastrointestinal cancer: a systematic review of assessment instruments.

Authors:  Rachelle Pullmer; Wolfgang Linden; Katerina Rnic; Andrea Vodermaier
Journal:  Support Care Cancer       Date:  2014-05-28       Impact factor: 3.603

Review 2.  Palliative Care for People With Hepatocellular Carcinoma, and Specific Benefits for Older Adults.

Authors:  Christopher D Woodrell; Lissi Hansen; Thomas D Schiano; Nathan E Goldstein
Journal:  Clin Ther       Date:  2018-03-20       Impact factor: 3.393

3.  Quality of life changes in patients undergoing treatment for hepatocellular carcinoma.

Authors:  Wei-Chu Chie; Fang Yu; Mengqian Li; Lorena Baccaglini; Jane M Blazeby; Chin-Fu Hsiao; Herng-Chia Chiu; Ronnie T Poon; Naoko Mikoshiba; Gillian Al-Kadhimi; Nigel Heaton; Jozer Calara; Peter Collins; Katharine Caddick; Anna Costantini; Valerie Vilgrain; Chieh Chiang
Journal:  Qual Life Res       Date:  2015-05-06       Impact factor: 4.147

4.  Role functioning is associated with survival in patients with hepatocellular carcinoma.

Authors:  Adam Meier; Adam Yopp; Huram Mok; Pragathi Kandunoori; Jasmin Tiro; Amit G Singal
Journal:  Qual Life Res       Date:  2014-12-13       Impact factor: 4.147

5.  Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC.

Authors:  K J Hartrumpf; S Marquardt; T Werncke; T Murray; M M Kirstein; A Vogel; F Wacker; T Rodt
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-14       Impact factor: 4.553

6.  Development of a patient-reported outcome tool for assessing symptom burden during perioperative care in liver surgery: The MDASI-PeriOp-Hep.

Authors:  Xin Shelley Wang; Qiuling Shi; Loretta A Williams; Heather A Lillemoe; Ting-Yu Chen; Vijaya Gottumukkala; Araceli Garcia-Gonzalez; Donna Malveaux; Mona Kamal; Charles S Cleeland; Thomas A Aloia
Journal:  Eur J Oncol Nurs       Date:  2021-04-28       Impact factor: 2.588

7.  Anticancer effect of xanthohumol induces growth inhibition and apoptosis of human liver cancer through NF-κB/p53-apoptosis signaling pathway.

Authors:  Xiangqian Zhao; Kai Jiang; Bin Liang; Xiaoqiang Huang
Journal:  Oncol Rep       Date:  2015-11-26       Impact factor: 3.906

Review 8.  Value of quality of life analysis in liver cancer: A clinician's perspective.

Authors:  Leung Li; Winnie Yeo
Journal:  World J Hepatol       Date:  2017-07-18

9.  Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.

Authors:  Leung Li; Frankie Kf Mo; Stephen L Chan; Edwin P Hui; Nelson Sl Tang; Jane Koh; Linda Ks Leung; Annette Ny Poon; Joyce Hui; Cheuk M Chu; Kit F Lee; Brigette By Ma; Paul Bs Lai; Anthony Tc Chan; Simon Ch Yu; Winnie Yeo
Journal:  BMC Cancer       Date:  2017-01-04       Impact factor: 4.430

Review 10.  Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life.

Authors:  Daneng Li; Sabrina Sedano; Rebecca Allen; Jun Gong; May Cho; Sunil Sharma
Journal:  Cancers (Basel)       Date:  2019-06-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.